Clinical trial · no report yet · Phase 2

DUTRENEO trial: what clinicians have said so far

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

NCT03472274 ↗
Completed
Fundacion CRIS de Investigación para Vencer el Cáncer
Deep size, estimated: 301+ verified statements once built

We haven't built an HCP commentary report on DUTRENEO (durvalumab plus tremelimumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on DUTRENEO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
33 posts on X, typically up to 145 once built
1 YouTube video, typically up to 4 once built
1 video on X, typically up to 4 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.
Phase: Phase 2
Status: Completed
Conditions: Bladder Cancer
Interventions: Durvalumab; Tremelimumab; Cisplatin-based neoadjuvant chemotherapy
Arms: Cisplatin-based neoadjuvant chemotherapy · Active comparator
Durvalumab plus Tremelimumab · Experimental
Enrollment: 101
Primary outcomes: Antitumor activity
Sponsor: Fundacion CRIS de Investigación para Vencer el Cáncer with AstraZeneca, Apices Soluciones S.L.
Start: Oct 25, 2018
Primary completion: Apr 30, 2021
Results posted: No
Registry record: NCT03472274 · updated Apr 13, 2023

Publications

linked from the registry

Sibai M, Cervilla S, Grases D, Musulen E, Lazcano R, Mo CK, Davalos V, Fortian A, Bernat A, Romeo M, Tokheim C, Barretina J, Lazar AJ, Ding L; DUTRENEO Study Investigators; Grande E, Real FX, Esteller M, Bailey MH, Porta-Pardo E. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity. Cell Rep. 2025 Feb 25;44(2):115229. doi: 10.1016/j.celrep.2024.115229. Epub 2025 Jan 24. PubMed 39864059

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on DUTRENEO so far

Reports on the same drug or indication

The trial

Publications